Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
CNY 12.14
(2.53%)
CNY 12.14
(2.53%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 411.29 Million CNY | -11.94% |
| 2022 | 467.07 Million CNY | -38.66% |
| 2021 | 761.46 Million CNY | -9.33% |
| 2020 | 839.8 Million CNY | 11.03% |
| 2019 | 756.4 Million CNY | 28.19% |
| 2018 | 590.06 Million CNY | 16.95% |
| 2017 | 504.54 Million CNY | 0.28% |
| 2016 | 503.13 Million CNY | 47.22% |
| 2015 | 341.74 Million CNY | 20.21% |
| 2014 | 284.29 Million CNY | 26.58% |
| 2013 | 224.59 Million CNY | 74.47% |
| 2012 | 128.72 Million CNY | 44.06% |
| 2011 | 89.35 Million CNY | 64.79% |
| 2010 | 54.22 Million CNY | 79.29% |
| 2009 | 30.24 Million CNY | 28.13% |
| 2008 | 23.6 Million CNY | 19.11% |
| 2007 | 19.81 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 420.98 Million CNY | -8.99% |
| 2024 Q1 | 407.6 Million CNY | -0.9% |
| 2024 Q2 | 462.58 Million CNY | 13.49% |
| 2023 Q4 | 411.29 Million CNY | -18.55% |
| 2023 FY | 411.29 Million CNY | -11.94% |
| 2023 Q1 | 507.63 Million CNY | 8.68% |
| 2023 Q2 | 490.78 Million CNY | -3.32% |
| 2023 Q3 | 504.95 Million CNY | 2.89% |
| 2022 Q4 | 467.07 Million CNY | 9.38% |
| 2022 FY | 467.07 Million CNY | -38.66% |
| 2022 Q2 | 674.64 Million CNY | -4.91% |
| 2022 Q3 | 427.03 Million CNY | -36.7% |
| 2022 Q1 | 709.49 Million CNY | -6.83% |
| 2021 Q3 | 861.5 Million CNY | 1.33% |
| 2021 FY | 761.46 Million CNY | -9.33% |
| 2021 Q4 | 761.46 Million CNY | -11.61% |
| 2021 Q1 | 888.62 Million CNY | 5.81% |
| 2021 Q2 | 850.23 Million CNY | -4.32% |
| 2020 Q1 | 1.02 Billion CNY | 35.11% |
| 2020 Q4 | 839.8 Million CNY | -26.99% |
| 2020 FY | 839.8 Million CNY | 11.03% |
| 2020 Q2 | 1.19 Billion CNY | 17.42% |
| 2020 Q3 | 1.15 Billion CNY | -4.15% |
| 2019 Q3 | 633.9 Million CNY | 21.53% |
| 2019 Q4 | 756.4 Million CNY | 19.32% |
| 2019 Q1 | 533.56 Million CNY | -9.57% |
| 2019 Q2 | 521.6 Million CNY | -2.24% |
| 2019 FY | 756.4 Million CNY | 28.19% |
| 2018 Q1 | 532.67 Million CNY | 5.57% |
| 2018 Q3 | 573.98 Million CNY | 2.92% |
| 2018 FY | 590.06 Million CNY | 16.95% |
| 2018 Q4 | 590.06 Million CNY | 2.8% |
| 2018 Q2 | 557.7 Million CNY | 4.7% |
| 2017 Q2 | 503.76 Million CNY | 2.47% |
| 2017 Q3 | 532.34 Million CNY | 5.67% |
| 2017 Q4 | 504.54 Million CNY | -5.22% |
| 2017 FY | 504.54 Million CNY | 0.28% |
| 2017 Q1 | 491.63 Million CNY | -2.28% |
| 2016 Q1 | 335.24 Million CNY | -1.9% |
| 2016 FY | 503.13 Million CNY | 47.22% |
| 2016 Q4 | 503.13 Million CNY | -3.41% |
| 2016 Q2 | 464.91 Million CNY | 38.68% |
| 2016 Q3 | 520.86 Million CNY | 12.04% |
| 2015 Q1 | 287.23 Million CNY | 1.03% |
| 2015 Q4 | 341.74 Million CNY | 4.03% |
| 2015 FY | 341.74 Million CNY | 20.21% |
| 2015 Q2 | 309.74 Million CNY | 7.84% |
| 2015 Q3 | 328.5 Million CNY | 6.05% |
| 2014 Q3 | 251.07 Million CNY | 4.12% |
| 2014 Q2 | 241.15 Million CNY | -3.7% |
| 2014 Q1 | 250.41 Million CNY | 11.5% |
| 2014 FY | 284.29 Million CNY | 26.58% |
| 2014 Q4 | 284.29 Million CNY | 13.23% |
| 2013 Q1 | 139.66 Million CNY | 8.5% |
| 2013 FY | 224.59 Million CNY | 74.47% |
| 2013 Q2 | 142.54 Million CNY | 2.06% |
| 2013 Q4 | 224.59 Million CNY | 6.6% |
| 2013 Q3 | 210.69 Million CNY | 47.81% |
| 2012 FY | 128.72 Million CNY | 44.06% |
| 2012 Q1 | 99.11 Million CNY | 10.92% |
| 2012 Q2 | 110.57 Million CNY | 11.56% |
| 2012 Q3 | 120.51 Million CNY | 8.99% |
| 2012 Q4 | 128.72 Million CNY | 6.82% |
| 2011 Q3 | 90.18 Million CNY | -3.6% |
| 2011 Q1 | 66.88 Million CNY | 23.36% |
| 2011 FY | 89.35 Million CNY | 64.79% |
| 2011 Q4 | 89.35 Million CNY | -0.92% |
| 2011 Q2 | 93.55 Million CNY | 39.86% |
| 2010 Q3 | 46.72 Million CNY | -10.79% |
| 2010 FY | 54.22 Million CNY | 79.29% |
| 2010 Q2 | 52.37 Million CNY | 0.0% |
| 2010 Q4 | 54.22 Million CNY | 16.05% |
| 2009 Q4 | 30.24 Million CNY | 0.0% |
| 2009 FY | 30.24 Million CNY | 28.13% |
| 2008 FY | 23.6 Million CNY | 19.11% |
| 2007 FY | 19.81 Million CNY | 0.0% |